PharVision Advisers’s Epsium Enterprise EPSM Stock Holding History

PharVision Advisers’s Portfolio EPSM Stock Details EPSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,030	Closed	-$118K	–	1059
2025 Q3	$118K	Buy	+11,030	New	+$279K	0.07%	606

Other funds holding EPSM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IRAG

Investment Research & Advisory Group Atlanta, Georgia $324M AUM 22.57% 1-Year Est. Return

PharVision Advisers's EPSM Position: Q4 2025 in Review

PharVision Advisers sold out of Epsium Enterprise (EPSM) in Q4 2025, closing a stake of 11,030 shares — an estimated $118K sold.

PharVision Advisers first reported a position in EPSM in Q3 2025 and held it in 1 quarter. The position peaked at $118K in Q3 2025. 8 funds tracked by Wall St. Rank hold EPSM as of Q4 2025.

PharVision Advisers reported no remaining Epsium Enterprise position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 11,030 Epsium Enterprise shares in Q4 2025, an estimated $118K.
PharVision Advisers first reported a position in Epsium Enterprise in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Epsium Enterprise position peaked at $118K in Q3 2025.
8 funds tracked by Wall St. Rank held Epsium Enterprise as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.